Sandy Macrae

Sandy Macrae is the CEO of Sangamo Therapeutics. Prior to joining Sangamo, Sandy served as the Global Medical Officer at Takeda Pharmaceuticals from 2012-2016, where they were responsible for the company's medical affairs, regulatory affairs, pharmacovigilance, outcomes research and epidemiology, quantitative sciences, and knowledge and informatics.

Before their time at Takeda, Sandy spent 11 years at GlaxoSmithKline in a variety of roles, including Senior Vice President of Emerging Markets R&D, Vice President of Business Development, and Vice President and Global Lead of Clinical Development for the MIGU Therapy Area. In their role as Senior Vice President of Emerging Markets R&D, Sandy conceived, created, and built GSK's first-of-its-kind group to expand the company's global reach by providing strategies, clinical development, and regulatory resources to enter emerging markets and Asia Pacific.

Sandy has a wealth of experience in the pharmaceutical industry, with a focus on clinical development, business development, and global strategy. Under their leadership, Sangamo has continued to grow and thrive, developing groundbreaking new therapies to improve the lives of patients around the world.

Sandy Macrae studied at the University of Glasgow, where they earned a BSc and MBChB. Sandy then went on to the University of Cambridge to earn their PhD.

Some individuals on their team include Nathalie Dubois-Stringfellow - Senior Vice President, Product Development and Management, Prathyusha Duraibabu - SVP, CFO, and Bettina Cockroft - Senior Vice President, Chief Medical Officer.